Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Viking Therapeutics Posts 22% Placebo-Adjusted VK2735 Loss at Week 33 (NASDAQ: VKTX)

Viking Therapeutics (NASDAQ: VKTX) said VK2735 maintained up to 97% of weight loss after subjects moved to every-other-week dosing. Monthly dosing preserved up to 90% of weight loss. The results came from a 12-week maintenance study of the GLP-1/GIP agonist. Weekly dosing at 17.5 …

Vinay Lochav | 22 September 2026

Beam Global (NASDAQ: BEEM) Signs Drone Acquisition LOI, Targets U.S. Manufacturing

Beam Global (NASDAQ: BEEM) is an electrical products company. It signed a non-binding letter of intent to acquire a European drone technology company, a proposed transaction that would expand its activities into drones and AI-enhanced drone software. Completion remains conditional on due diligence, negotiations, …

Vinay Lochav | 22 September 2026

Leviticus Partners Holds 235,000 Harvard Bioscience (NASDAQ: HBIO) Shares

Harvard Bioscience Inc (NASDAQ: HBIO) has a 5.2% ownership position held by Leviticus Partners LP. The reported interest covers 235,000 common shares.

Vinay Lochav | 22 September 2026

Immuron (NASDAQ: IMRN) Expands Travelan Sales Plans and IMM-529 Partnering Efforts

Immuron Ltd (NASDAQ: IMRN), a Pharmaceuticals: Major company, says its $9 million cash balance is sufficient to fund commercial operations. TheBusinessis pursuing a strategic reset that places IMM-124E and IMM-529 with partners for development and commercialization.

Vinay Lochav | 22 September 2026

Immutep (NASDAQ: IMMP) Sets September 28 ADS Conversion Ahead of Nasdaq Deadline

Immutep Limited (NASDAQ: IMMP) is a biotechnology company. Its ADS count is expected to move from approximately 32.8 million to approximately 1.64 million when a revised ADS ratio takes effect on September 28, 2026. The change is aimed at helping the Nasdaq-listed ADSs meet …

Vinay Lochav | 22 September 2026

KAZIA Therapeutics (NASDAQ: KZIA) Reaches First-Patient Milestone in Paxalisib Trial

Sovargen Trial Reaches First-Patient Milestone

Vinay Lochav | 22 September 2026

Kazia Therapeutics (NASDAQ: KZIA) Reaches Paxalisib Seizure Trial Milestone

The milestone extends paxalisib development beyond oncology into intractable epilepsy associated with focal cortical dysplasia and tuberous sclerosis complex.

Vinay Lochav | 22 September 2026

Alibaba Group Retains 46.9 Million ZTO (NYSE: ZTO) Shares After Stake Reduction

Alibaba Group Holding Limited’s activist stake in ZTO Express (Cayman) Inc. (NYSE: ZTO) fell to 6.1%, representing 46,941,287 Class A ordinary shares (46.9 million). The position is reported under Schedule 13D, which identifies activist rather than passive ownership intent. The change was recorded on …

Vinay Lochav | 22 September 2026

Adagene (NASDAQ: ADAG) Secures NMPA IND Clearance for ADG138 Phase 1 Study

Adagene Inc. received China’s NMPA clearance for ADG138’s investigational new drug application, with a first-in-human Phase 1 study in advanced solid tumors expected in the fourth quarter of 2026. The study is designed to assess safety, preliminary efficacy and the recommended dose for Phase …

Vinay Lochav | 22 September 2026

Advanced Biomed (NASDAQ: ADVB) Reports 6.6% Stake Held by Advance On Ventures Limited

Advanced Biomed Inc. (NASDAQ: ADVB) is a biotechnology company. Advance On Ventures Limited holds 109,200 shares of Advanced Biomed common stock, representing 6.6% ownership.

Vinay Lochav | 22 September 2026
Support

Hi! How can we help you today?

Loading…